Press Release


Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study
Feb 04, 2019 11:57 JST
Eisai Co., Ltd. and Purdue Pharma L.P. announced a six-month results from SUNRISE 2, a long-term Phase 3 clinical study evaluating the efficacy and safety of lemborexant, an investigational agent being developed for the treatment of insomnia, a sleep-wake disorder.
More info..

Eisai's Supplementary New Drug Application Submitted In Japan for Fycompa
Jan 30, 2019 15:22 JST
Eisai Co., Ltd. has filed a supplementary new drug application in Japan for its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) seeking approval for use as monotherapy for partial-onset seizures, treatment for partial-onset seizures in pediatric patients aged 4 years and older, as well as a new fine granule formulation.
More info..

Eisai Listed as a Global 100 Most Sustainable Corporation for the Fourth Time
Jan 22, 2019 16:54 JST
Eisai Co., Ltd. has been listed in the 2019 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc.
More info..

Eisai's Notification Regarding Results of Voluntary Retirement Program
Jan 18, 2019 13:33 JST
Eisai Co., Ltd. announced today that the application period for the first round of the voluntary retirement program it announced on October 25, 2018, has ended and hereby discloses the results.
More info..

Eisai to Present Results of Post-Hoc Analyses of Lenvima (Lenvatinib) Phase III Reflect Study in Hepatocellular Carcinoma at 2019 Gastrointestinal Cancers Symposium
Jan 15, 2019 13:31 JST
Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting the latest data from post-hoc analyses of a Phase III clinical study (REFLECT/Study 304) on its in-house discovered multiple receptor tyrosine kinase inhibitor lenvatinib mesylate as first-line treatment for unresectable hepatocellular carcinoma (HCC) will be presented during the 2019 Gastrointestinal Cancers Symposium (ASCO-GI) in San Francisco.
More info..

Eisai's New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
Jan 15, 2019 13:23 JST
Eisai Co., Ltd. and Purdue Pharma L.P. today announced that a new drug application has been submitted to the U.S. Food and Drug Administration (FDA) for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for the treatment of insomnia, a sleep-wake disorder.
More info..

Eisai's Etak Antimicrobial Spray Alpha Wins Nikkei Business Daily Awards for Superiority at the 2018 Nikkei Superior Products and Services Awards
Jan 04, 2019 11:18 JST
Eisai Co., Ltd. has announced that it received a "Nikkei Business Daily Awards for Superiority" for its Etak Antimicrobial Spray Alpha, which contains long-acting antimicrobial agent Etak, at the 2018 Nikkei Superior Products and Services Awards sponsored by Nikkei Inc.
More info..

Eisai's New Drug Application for Perampanel Designated for Priority Review by China National Medical Products Administration
Jan 04, 2019 08:39 JST
Eisai Co., Ltd. announced that its in-house discovered and developed AED perampanel, for which a NDA was submitted for review as an adjunctive treatment for partial onset seizures in epilepsy patients 12 years of age and older in China in October 2018, has been designated for Priority Review by the NMPA due to perampanel's significant clinical benefit compared to existing treatments.
More info..

Eisai: Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3's RNA Splicing Platform
Dec 18, 2018 10:38 JST
Bristol-Myers Squibb Company, Eisai Co., Ltd. and its U.S.-based precision medicine research & development subsidiary H3 Biomedicine, Inc. has announced a multi-year research collaboration focused on evaluating whether novel therapeutics leveraging H3's RNA splicing platform can provide a more powerful response against cancer.
More info..

Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Brazil with Eurofarma
Dec 17, 2018 08:21 JST
Under this agreement, Eisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for sales in Brazil.
More info..

GARDP, Eisai and Takeda Announce Partnership in the Search for New Antibiotics
Dec 12, 2018 09:06 JST
The Global Antibiotic Research and Development Partnership (GARDP), Eisai Co., Ltd. and Takeda Pharmaceutical Company Limited have signed an agreement for GARDP to access and screen components of Eisai and Takeda's chemical libraries.
More info..

Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research
Dec 06, 2018 09:24 JST
Eisai Co., Ltd. and University College London (UCL) announced today that they have commenced preparations for Phase I clinical studies on E2814, the first clinical candidate from their drug discovery collaboration, in Alzheimer's disease patients within fiscal 2018.
More info..

Eisai: MOVICOL Launched in Japan
Nov 29, 2018 13:48 JST
MOVICOL is the first polyethylene glycol preparation indicated for treatment of chronic constipation in Japan, available for adults and children 2 years of age and older.
More info..

Eisai: Primary Endpoint Met in Phase III Clinical Study of Fycompa
Nov 28, 2018 10:55 JST
Eisai Co., Ltd. announced today that based on topline results, the primary efficacy endpoint was met in a Phase III clinical study (Study 342) conducted for submission in Japan, which evaluated its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) as monotherapy for partial-onset seizures.
More info..

Eisai to Present New Research on Eribulin (Halaven) at 41st Annual San Antonio Breast Cancer Symposium
Nov 27, 2018 17:02 JST
Eisai Co., Ltd. announced today that the latest information on its in-house discovered and developed anticancer agent eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN, "eribulin") will be presented during the 41st San Antonio Breast Cancer Symposium (SABCS).
More info..

Eisai to Present Latest Data on Perampanel at 72nd American Epilepsy Society Annual Meeting
Nov 23, 2018 07:14 JST
Eisai Co., Ltd. announced that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 72nd American Epilepsy Society Annual Meeting (AES 2018) to be held from November 30 to December 4, 2018 in New Orleans in the United States.
More info..

Eisai Receives "IR Grand Prix Award"
Nov 14, 2018 12:30 JST
Eisai Co., Ltd. has announced that it received the "IR Grand Prix Award" at the IR Award 2018 held by the Japan Investor Relations Association (JIRA).
More info..

Eisai Launches Lenvima (Lenvatinib) in China
Nov 12, 2018 11:51 JST
Eisai Co., Ltd. announced that its Chinese subsidiary Eisai China Inc. (ECI) has launched the kinase inhibitor LENVIMA (generic name: lenvatinib mesylate) in China.
More info..

Eisai: New Data from Investigational Study of Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
Nov 09, 2018 08:08 JST
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, today announced results from presentations of new data and analyses of LENVIMA, an orally available kinase inhibitor discovered by Eisai, in combination with Merck's & Co., Inc.'s anti-PD-1 therapy KEYTRUDA in three different tumor types - metastatic non-small cell lung cancer (NSCLC), metastatic melanoma and metastatic urothelial carcinoma.
More info..

Eisai: Industry-Academia-Government Joint Development Agreement Concerning Anti-Fractalkine Antibody E6011 for Treatment of Crohn's Disease Concluded, Research Activities Commence
Nov 08, 2018 14:38 JST
Eisai Co., Ltd. and Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. announced today that EA Pharma has entered into an industry-academia-government joint research agreement with six related joint research organizations, and that research activities have fully commenced.
More info..

Eisai Commences Full-Scale Operation of New Suzhou Plant in China
Nov 08, 2018 08:43 JST
Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has commenced full-scale operation of its new Suzhou plant located within the Suzhou Industrial Park, and an opening ceremony was held accordingly.
More info..

Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at CTAD
Oct 29, 2018 08:45 JST
Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease (CTAD) meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension (LTE) of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD.
More info..

Eisai Presents New Data on Lemborexant for Treatment of Irregular Sleep-Wake Rhythm Disorder in Patients With Alzheimer's Disease
Oct 26, 2018 08:32 JST
Eisai Co., Ltd. announced that Eisai presented new data from Study 202, a Phase II evaluation of lemborexant, an investigational sleep-wake regulation agent, for the treatment of Irregular Sleep-Wake Rhythm Disorder (ISWRD) in patients with mild to moderate Alzheimer's disease.
More info..

Eisai and Biogen Announce Presentation of Additional Data from Phase II Clinical Trial of BAN2401 in Early Alzheimer's Disease
Oct 26, 2018 07:03 JST
Eisai presented the latest data from the Phase II clinical study (Study 201) of BAN2401 at a symposium session titled "Clinical and Biomarker Updates from BAN2401 Study 201 in Early Alzheimer's Disease" held on October 25 at the 11th CTAD conference in Barcelona, Spain.
More info..

Eisai to Present Latest Data on Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination and Exploratory Research
Oct 25, 2018 08:05 JST
Eisai Co., Ltd. announced today that the latest data regarding its in-house discovered kinase inhibitor lenvatinib mesylate, in combination with Merck & Co.'s anti-PD-1 therapy pembrolizumab, and exploratory research on the STING (stimulator of interferon genes) agonist E7766 as cancer immunotherapy will be presented during the 33rd Annual Meeting of the SITC.
More info..

Eisai: Application Seeking Manufacturing and Marketing Approval in Japan Submitted for Parkinson's Disease Treatment Safinamide
Oct 23, 2018 14:13 JST
Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced that an application seeking manufacturing and marketing approval in Japan was submitted as of today by Meiji for the Parkinson's disease treatment ME2125 (safinamide mesylate, "safinamide").
More info..

Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan
Oct 22, 2018 16:34 JST
Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that the two companies have commenced joint medical and marketing activities for tyrosine kinase inhibitor LENVIMA (generic name: lenvatinib mesylate) in Japan.
More info..

Eisai: Discovery of Candidate Compound as Potential Treatment for Parkinson's Disease Using iPS Cells
Oct 19, 2018 11:18 JST
A joint research group centered around Professor Hideyuki Okano and Associate Professor Jun Kohyama, Department of Physiology of the Keio University School of Medicine, together with a research group of Eisai Co., Ltd. has identified a compound that has the potential to be a treatment for Parkinson's disease by using dopaminergic neurons differentiated from induced pluripotent stem (iPS) cells from patients with familial Parkinson's disease.
More info..

Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 11th Clinical Trials on Alzheimer's Disease Conference
Oct 18, 2018 08:03 JST
Eisai Co., Ltd. announced today that five oral presentations including a symposium, and two poster presentations.
More info..

Latest Release


More Latest Release >>